We use cookies on our website. Carry on browsing if you’re happy with this or find out more

Board of Directors, Executive Leadership

:

Arndt Schottelius, MD PhD

arndt schottelius

Dr Schottelius has over 20 years' experience in the pharmaceutical industry. He joined Kymab from MorphoSys AG, where he served as its first Chief Development Officer, building the development area and portfolio of proprietary therapeutic antibody programmes in cancer and immunology.

Prior to his role with MorphoSys, Dr Schottelius was Medical Director, Immunology Development at Genentech Inc., South San Francisco, where he directed early- and late-stage clinical development programmes of therapeutic antibodies. Before joining Genentech, Dr Schottelius held science and management positions in immunology research at Schering AG, Berlin, Germany and Berlex Biosciences, Richmond, California.

Dr Schottelius studied medicine in Freiburg, Germany, and at the Royal Free Hospital in London and received his PhD and MD degrees from the University of Freiburg, Germany. Subsequently, he practiced medicine as a resident physician in gastroenterology at the Charité-Universitätsmedizin Berlin, Germany, and held a research fellowship from the Crohn's & Colitis Foundation of America at the University of North Carolina at Chapel Hill before moving into the pharmaceutical industry.